Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J - LARVOL DELTA

Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort. (PubMed, HIV Med) - "Switching from 2DR-INSTI to B/F/TAF is infrequent; this switch results in a low rate of toxicity and failure, along with a favourable immunovirological and lipid profile. CD4/CD8 gain is observed in those switching with detectable HIV-RNA."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Long-Acting Cabotegravir and Rilpivirine in Older People With HIV in the GEPPO Cohort (CROI 2025) - "Background The association of intramuscularly administered Long-acting cabotegravir and rilpivirine (LA CAB+RPV) has been proven to be effective and safe in the maintenance treatment of people with HIV (PWH)...The pre-switch regimen was mainly based on a three-drug combination in 53.5% of study participants (mostly bictegravir or rilpivirine-based) or two-drug combinations by 45.1% (mostly dolutegravir/rilpivirine and dolutegravir/lamivudine)...Conclusions Our results suggest that the LA CAB+RPV combination is effective and safe in OPWH despite a long history of ART and a high prevalence of multimorbidity and polypharmacy. Older age should not be a barrier to the LA regimen: this study paves the way to evaluate the risk of an ageism attitude when clinicians consider ART choices in older PWH."

Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pain • CD4

Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir (CROI 2025) - "The aim of this study was to evaluate the incidence of HBV reactivation in PWH with isolated anti-core pattern who are treated with dual ART regimens lacking TXF: DTG+3TC, DTG+RPV, or CAB+RPV-LA. Conclusions Our findings suggest that the risk of HBV reactivation in PLHIV with isolated anti-core patterns who are treated with TXF-free dual ART regimens is extremely low after more than 3 years of follow-up. This holds true even for regimens that do not have direct anti-HBV activity, such as DTG+RPV and CAB+RPV-LA."

Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

ART Exposure and Accelerated Aging in PLHIV: Insights From Proteomic and Methylation Clocks (CROI 2025) - P | "Longer cumulative exposure to dolutegravir (DTG), rilpivirine (RPV) and nelfinavir (NFV) was associated with lower age advancement scores on at least a biological clock. In contrast, longer exposure to tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), darunavir (DRV), atazanavir (ATV), and dideoxynucleoside analogues (d-drugs) was related to higher age advancement scores (Figure 1; P<0.05, adjusted for chronological age)...Conclusions Cumulative ART exposure influences age acceleration in PLHIV, with distinct effects across regimens and drug classes. Innate immune pathways appear to be key drivers of these effects and are promising therapeutic targets to mitigate accelerated aging."

Human Immunodeficiency Virus • Infectious Disease • Inflammation

Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes (CROI 2025) - "We aimed to compare virologic suppression (VS) in treatment-experienced persons with HIV following switch to DTG+DOR versus DTG+RPV. Conclusions Observed differences in VS following switch to DRG+RPV and DTG+DOR may be due to differences in participant characteristics, adherence, viral resistance patterns, and the dual regimens. Further studies are needed to evaluate efficacy of dual NRTI-free regimens in real-world settings."

Chronic Kidney Disease • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Renal Disease • CD4

Immediate virological failure with intramuscular cabotegravir-rilpivirine in a patient long suppressed with dolutegravir-rilpivirine. (PubMed, AIDS) - No abstract available

Journal

Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks. (PubMed, Medicine (Baltimore)) - "This observational study collected demographics, clinical characteristics, weight, and BMI from virologically suppressed adults switched to BIC/emtricitabine/tenofovir alafenamide (TAF), emtricitabine/TAF plus DTG, DTG/abacavir/lamivudine, DTG/rilpivirine (RPV), and DTG/lamivudine 2 years prior to switch through 144 weeks post-switch...DTG plus emtricitabine/TAF switches had the highest annualized weight gain (0.68 kg/year, 95% confidence interval: -0.32, 1.65) whereas, DTG/RPV switches had the lowest annualized weight gain (-2.22 kg/year, 95% confidence interval: -3.69, -0.62) post-switch...Baseline BMI < 18.5 kg/m2 was associated with the highest annualized weight gain post-switch, whereas switching from protease inhibitors and self-report of dieting were associated with the lowest annualized weight gain post-switch. At week 144, switching to a BIC versus DBR were both associated with lower annualized weight gain post-switch among a large and diverse cohort of..."

Journal • Observational data • Human Immunodeficiency Virus • Infectious Disease

Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens. (PubMed, AIDS) - "In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs. Generalized additive mixed models were used to examine LDL cholesterol dynamics. LDL cholesterol was measured in 2381 PWH: during the first two years, DOR had the greatest lowering effect and showed the most favorable lipid outcome."

Journal • Observational data • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease

The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis. (PubMed, AIDS) - "Hemodialysis did not lead to clinically appreciable differential exposures to DTG and RPV. Exposures throughout the dosing interval were greater than the reported protein-binding-adjusted IC90 efficacy values for DTG (64 ng/ml) and RPV (12 ng/ml) in all participants. These data suggest no dosing modifications are needed for the FDC DTG+RPV regimen in hemodialysis."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Antiretroviral therapy in people with HIV and end-stage kidney disease. (PubMed, AIDS) - "Dual/unboosted ART regimens such as dolutegravir/lamivudine provide robust viral efficacy in the setting of ESKD, and higher than recommended, including full-dose, lamivudine was well tolerated. The dolutegravir/lamivudine (300 mg) fixed-dose combination provides a single-tablet regimen for use across the eGFR spectrum, avoids under-exposure to lamivudine, and merits further evaluation in this population."

Journal • Chronic Kidney Disease • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Renal Disease • Transplantation • CD4

Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV‐1 receiving calcineurin and mTOR inhibitors: a pilot switch study (HIV-Glasgow 2024) - " Five HIV-KTR were enrolled and were receiving 3TC/ABC+RAL (n = 4) or RPV+DTG (n = 1) before switching to B/F/TAF: two women, median (IQR) age 58 (48–66) years and BMI 25.0 kg/m2 (20.6–26.), two with AIDS...In addition to corticosteroids, the immunosuppressant regimen included calcineurin inhibitors (cyclosporine n = 1, mycophenolate mofetil n = 3, tacrolimus n = 1) and mTOR inhibitors (everolimus n = 2)... This pilot study shows that B/F/TAF appears to be safe and effective in HIV-KTR receiving calcineurin and mTOR inhibitors."

Clinical • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nephrology • Renal Disease • Transplantation • CD4 • CD8

Cabotegravir‐rilpivirine long‐acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort (HIV-Glasgow 2024) - "Before starting the injectables, 32 patients took a triple oral therapy (regimen mostly used: TAF/FTC/RPV), while 33 assumed a 2DR regimen (regimens mostly used: DTG/3TC-DTG/RPV); as a whole, 42 took an INSTI-based regimen... 1.8% of our cohort experienced a VF; this result is coherent with the main studies evaluating a low failure rate of CAB-RPV. CAB-RPV L-A regimen was well-tolerated. Respect of eligibility criteria and awareness of risk factors for VF plus strict monitoring of viro-immunological parameters are fundamental in reducing the risk of VF and the possible onset of new NNRTI/INSTI resistance mutations."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Pain

Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going (HIV-Glasgow 2024) - "There were 181 (28.2%) patients who came from regimens with another integrase inhibitor with cobicistat (EVGc/TAF/FTC) and 98 (15.3%) patients who did not have INSTI in their ART (RPV/TAF/FTC, DRVc/TAF/FTC or EFV/TAF/FTC)...Of the remaining 66 PLWH who switched to other treatments, most of them switched to intramuscular CAB/RPV (24; 36.4%), followed by oral dual therapies such as DTG/3TC (17; 25.8%) or DTG/RPV (4; 6%)... Antiretroviral therapy with BIC/FTC/TAF is the most commonly used ART in our hospital, being a safe therapy that is generally maintained over time and suitable for PLWH co-infected with HBV. The main reason for discontinuation is the participant's desire to switch to intramuscular therapies."

Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Causes of discontinuation of long‐acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort (HIV-Glasgow 2024) - "Adverse events leading to discontinuation of long-acting therapy with cabotegravir/rilpivirine in SCOLTA cohort Sex at birth, age Previous regimen Pain/local reaction Fever Other Causal correlation with therapy Days since first injection 1 F, 59 3TC/DTG Yes, G 3 No No Certain 132 2 M, 67 3TC/DTG Yes, G 2 Yes, G 2 No Certain 56 3 M, 55 RPV/DTG Yes, G 2 No No Certain 29 4 M, 40 RPV/DTG Yes, G 2 No No Certain 28 5 M, 61 RPV/DTG Yes, G 2 No No Certain 56 6 M, 54 FTC/TAF/BIC Yes, G 2 No No Certain 445 7 M, 55 FTC/TAF/BIC Yes, G 1 No No Certain 64 8 M, 35 FTC/TAF/BIC No Yes, G 3 No Certain 112 9 M, 44 RPV/DTG No Yes, G 2 Arthromyalgia, G 2 Possible 87 10 M, 49 3TC/DTG No Yes, G 2 No Probable 1 11 M, 32 3TC/DTG No Yes, G 1 No Unlikely 94 12 F, 65 RPV/DTG No Yes, G 1 No Possible 181 13 M, 56 3TC/ABC/DTG No No Difficulty walking, G 3; weight gain, G 1 Unlikely for both 87 14 M, 46 RPV/DTG No No Arthromyalgia, G NA Certain 30 15 M, 59 FTC/TAF/BIC No No Arthromyalgia, G 1 Probable..."

Clinical • CNS Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Migraine • Musculoskeletal Pain • Pain • Pancreatitis

Switching to LA CAB/RPV in virologically suppressed PLHIV: does knowing previous genotyping really matter? A substudy from the RELATIVITY cohort (HIV-Glasgow 2024) - "Switching from DTG/RPV (27.5% vs. 19.6%; p < 0.001) or DRV/b-based regimens (8.2% vs. 3.6%; p < 0.001) was more frequent when genotyping was unavailable. Our results suggest that unavailability of previous genotyping does not seem to increase the risk of virological failure in virologically suppressed PLHIV who switch to LA CAB/RPV. These seem to line up with the results of the CARES study [1]. Nevertheless, a longer follow up is required to reach solid conclusions."

CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Mental Retardation • Psychiatry • CD4

To describe the prevalence of virological failure and resistance patterns to long‐acting cabotegravir‐ rilpivirine: a real‐life single‐centre cohort study (HIV-Glasgow 2024) - "Background: Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) is currently used as maintenance treatment for HIV-1. In our series, at week 28, the rate of VF (two consecutive VL >50 cp/ml) was low (1.25%), all of them were with low-level viraemias (<200 copies/ml) and the resistance mutations detected may reflect APOBEC activity and should be carefully interpreted by a resistance specialist."

Clinical • Human Immunodeficiency Virus • Infectious Disease • APOB

Long‐acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real‐world study (RELATIVITY Cohort) (HIV-Glasgow 2024) - "Background: Switching to long-acting cabotegravir and rilpivirine (CAB+RPV) has emerged as a standard approach for people living with HIV, offering high efficacy, safety and convenience...The most frequent antiretrovirals strategies before switching included DTG/3TC (27.4%), DTG/RPV (23%), BIC/FTC/TAF (20.3%) and DRV/c/FTC/TAF (14.2%)... In a real-life setting, switching to long-acting CAB+RPV seems to be a viable option for individuals with a BMI over 30, lining up with other cohorts. Further investigation is needed."

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • CD4

Patient‐reported outcomes in switching to long‐acting cabotegravir/rilpivirine: a real‐life experience (HIV-Glasgow 2024) - " Thirty-six patients have joined it, via own mobile phone; 11 assigned female at birth (30.5%), with a median age of 47 years (range 29–68), 11% with a AIDS history; pre-switch treatment were: DTG/3TC (27.8%), RPV/TAF/FTC (25%), BIC/TAF/FTC (22.2%), DTG/RPV (11%), DRV/cobi/TAF/FTC (5.6%), TDF/FTC + RAL (2.8%), TDF/FTC/ABC (2.8%), DRV+RTV+3TC+ETV (2.8%). For patients who agree to the therapeutic switch, CAB/RPV LA is a well-tolerated therapy that improves quality of life and own relationship with the infection."

Clinical • Patient reported outcomes • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Pain • Psychiatry • RBL1

Transforming HIV care: intramuscular bimonthly cabotegravir and rilpivirine for transgender people with HIV in Spain (RELATIVITY cohort) (HIV-Glasgow 2024) - "DTG+RPV was previous oral ART regimen in 50%. This descriptive analysis highlights successful ART management of transgender people with HIV using CAB+RPV LA IM regimen. Further research is needed to understand broader treatment dynamics and outcomes in diverse transgender populations."

Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Switching to long‐acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine: a substudy from the RELATIVITY cohort (HIV-Glasgow 2024) - "Materials and The RELATIVITY cohort is a multicentre, non-controlled, ambispective study on HIV virologically suppressed individuals who switched to LAI CAB+RPV. In real-life settings, switching from DTG+RPV to CAB+RPV is safe and well tolerated. Our results suggest that in virologically suppressed PLHIV under treatment with DTG/RPV, previous genotyping results might not be necessary in order to switch to CAB+RPV."

Cardiovascular • CNS Disorders • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Mental Retardation • Psychiatry

Safety and efficacy of switch to bictegravir/emtricitabine/tenofovir alafenamide fumarate following dual regimen therapy in HIV: insights from the Icona cohort (HIV-Glasgow 2024) - " We included all PWH enrolled in the ICONA cohort who started B/F/TAF after a period of treatment with 2DR INSTI-based (3TC/DTG, RPV/DTG, RPV/CAB or DOR+DTG). Switching from 2DR-INSTI to B/F/TAF is infrequent; this switch results in a low rate of toxicity/failure and a good immuno-virological and lipid profile. CD4/CD8 gain is observed as a result of achieving undetectable HIV-RNA. P143: Figure 1Open in figure viewerPowerPoint (left) Characteristics of 60 people with HIV treated with 2DR INSTI-based who started treatment with B/F/TAF; (right) slopes from fitting linear mixed models adjusted for age and sex with change at B/F/TAF switch."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

HIV infection in migrant women from sub‐Saharan Africa in North East of Italy: a snapshot of a vulnerable population (HIV-Glasgow 2024) - "Four hundred and twenty-eight (99.1%) women were receiving antiretroviral therapy (ART); 78.9% and 15.7% of them were on triple therapy (34% INI, 16.8% PI, 28.3% NNRTI), and on dual therapy (DTG+RPV, XTC+DTG or XTC+PI/b), respectively... Over 99% of SSA WLWH in care at our ID centres received ART, but only 78.2% were virologically suppressed. Unstable socio-economic conditions, language barriers and lack of education likely contributed to poor ART adherence. In addition, a significant number of women were diagnosed with HIV after arriving in Italy, underscoring the need for targeted HIV prevention and testing programmes to prevent late HIV diagnoses, which are significantly higher among migrant women in our cohort compared to those in other European countries."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Respiratory Diseases • Tuberculosis • CD4

T‐cell homeostasis and microbial translocation in PLWH switching from triple to dual INSTI‐based combination antiretroviral therapy (cART) (HIV-Glasgow 2024) - "Demographic and clinical features of the study population (n = 60) on suppressive 3DR (pre-switch) Age, years, median (IQR) 48 (42−58) Sex male, n (%) 50 (83.33%) Risk factors for HIV infection MSM, n (%) 40 (66.66%) Risk factors for HIV infection heterosexual, n (%) 17 (28.33%) Time since HIV diagnosis (years), median (IQR) 14 (10−18) Time on cART (years), median (IQR) 13 (10−18) Time from switch (months), median (IQR) 11 (8−14.7) CD4 cell count nadir (cells/mm3), median (IQR) 275 (182.5−407.5) HIV RNA (copies/ml) pre-switch, median (IQR) 0 (0−0) Total time with viral load <50 copies/ml (years), median (IQR) 9 (7−9) Past AIDS-defining events (CDC C), n (%) 9 (15%) Number of cART lines prior to switch 0−3, n (%) 47 (78.33%) Number of cART lines prior to switch 4−8, n (%) 11 (18.33%) Pre-switch 3DR cART INSTI-based, n (%) 41 (68.33%) Pre-switch 3DR cART NNRTI-based, n (%) 14 (23.33%) Post-switch 2DR cART 3TC/DTG, n (%) 53 (88.33%) Post-switch 2DR cART DTG/RPV, n (%) 7..."

IO biomarker • Gastrointestinal Disorder • Human Immunodeficiency Virus • Infectious Disease • CD38 • CD8 • CDH1 • IL7R • STAT2

Real‐world utilization of cabotegravir + rilpivirine in Southern Spain: data from the CARIPLA study (HIV-Glasgow 2024) - "Prior regimens: DTG/3TC (30.6%), TAF/FTC/BIC (26.6%), DTG/RPV (12.0%), TAF/FTC/RPV (9.6%), TAF/FTC/DRVc (3.2%) and others (17.7%). CAB+RPV was effective and safe in long-term and highly ART-experienced HIV-infected patients under any prior treatment, suggesting high effectiveness of this regimen in real-world settings. Convenience and simplification were the main reasons for changing, and DTG-based dual therapies were the most common prior regimens. Few patients discontinued CAB+RPV, exceptionally due to adverse event."

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • Pain • CD4

Real‐world persistence of bictegravir‐ versus dolutegravir‐based single tablet regimens in a large urban Canadian HIV centre (HIV-Glasgow 2024) - "Materials and We compared the persistence (i.e. the lack of regimen discontinuation) between BIC/FTC/TAF and DTG-containing STRs, combined and individually (ABC/3TC/DTG, 3TC/DTG, RPV/DTG). STRs containing INSTIs proved to have robust persistence with discontinuations less than 30% with a long median time to discontinuation of 402 days. BIC/FTC/TAF had a preferable portfolio of persistence over DTG-containing STR regimens overall and ABC/3TC/DTG, making it a continued important choice as an ART in first-line therapy and for switch."

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease